Inspire Medical Systems (NYSE:INSP) CEO Timothy P. Herbert Sells 9,832 Shares
Inspire Medical Systems (NYSE:INSP) CEO Timothy P. Herbert sold 9,832 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $80.10, for a total value of $787,543.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of NYSE:INSP traded up $1.15 on Wednesday, reaching $81.25. 195,005 shares of the company traded hands, compared to its average volume of 262,850. Inspire Medical Systems has a fifty-two week low of $46.00 and a fifty-two week high of $82.15. The company’s 50 day moving average is $74.00 and its 200-day moving average is $66.09. The stock has a market capitalization of $1.91 billion, a PE ratio of -54.17 and a beta of 1.26. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.42 and a quick ratio of 13.05.
Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.09. Inspire Medical Systems had a negative return on equity of 18.67% and a negative net margin of 40.36%. The company had revenue of $20.86 million during the quarter, compared to the consensus estimate of $19.15 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The company’s quarterly revenue was up 59.8% compared to the same quarter last year. As a group, analysts expect that Inspire Medical Systems will post -1.46 EPS for the current year.
A number of equities research analysts have recently commented on INSP shares. Zacks Investment Research downgraded Inspire Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, January 4th. Berenberg Bank upgraded Inspire Medical Systems from a “sell” rating to a “hold” rating and increased their price objective for the company from $46.00 to $51.00 in a research report on Wednesday, November 6th. Dougherty & Co set a $78.00 price objective on Inspire Medical Systems and gave the company a “buy” rating in a research report on Friday, September 27th. Finally, ValuEngine downgraded Inspire Medical Systems from a “hold” rating to a “sell” rating in a research report on Friday, January 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. Inspire Medical Systems has a consensus rating of “Hold” and a consensus price target of $68.25.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.